Carl Harald Jansonm, lead investment manager on the International Biotechnology investment trust, looks at how the sector has fared following the most recent sell-off
The US biotechnology sector’s stupendous bull run went into sharp reverse in August when the NASDAQ biotechnology index plunged by more than 20% from its peak value in July, before recovering. The...
Effective from 1 January
Industry Voice: Many investment portfolios that rely heavily on stock-bond diversification to manage risks may not be protected against inflation surprises. Real assets offer a solution.